INDICATIONS
The AD regimen ( Table 1) has been studied for adjuvant or neoadjuvant therapy of operable soft tissue sarcoma and primary therapy of metastatic or inoperable soft tissue sarcoma. [1] [2] [3] Current guidelines list it as an option for the treatment of advanced, unresectable, metastatic, or recurrent disease. 4 
DRUG PREPARATION
Follow institutional policies for preparation of hazardous medications when preparing and dispensing doxorubicin and dacarbazine. A. Doxorubicin 1. Use doxorubicin injection 2 mg/mL, or doxorubicin powder for injection. 2. Reconstitute the powder with 0.9% sodium chloride (NS) to a concentration of 2 mg/mL.
3. Dilute in 250 to 1,000 mL of NS, 5% dextrose in water (D5W), or a saline dextrose solution for continuous infusion or bolus infusion. B. Dacarbazine 1. Use dacarbazine powder for injection. 2. Reconstitute with sterile water for injection, NS, or D5W to a concentration of 10 mg/mL. 3. Dilute with 250 mL to 1,000 mL NS, D5W, or a saline/dextrose solution. 4. Since dacarbazine is light sensitive, the solution should be protected from light immediately following preparation.
5
C. Doxorubicin and dacarbazine may be mixed in the same container and administered as a single infusion.
2,3,5

DRUG ADMINISTRATION
In the AD regimen, doxorubicin and dacarbazine are administered as continuous (24 hour) intravenous (IV) infusions.
SUPPORTIVE CARE
A. Acute and Delayed Emesis Prophylaxis:
The AD regimen is predicted to cause acute emesis in greater than 90% of patients. [6] [7] [8] [9] The studies reviewed reported moderate or worse nausea and vomiting in 51% to 77% of patients and severe or worse nausea and vomiting in 9% to 29%. [1] [2] [3] In patients receiving bolus therapy, Borden et al reported moderate or worse nausea or vomiting in 77% and severe nausea or vomiting in 29% of patients, respectively.
2 Continuous infusion of AD was associated with moderate or severe nausea and vomiting in 51% versus 64% in the bolus arm in the study by Zalupski et al. 3 Appropriate acute emesis prophylaxis includes a serotonin antagonist, a corticosteroid, and a neurokinin (NK 1 ) antagonist. [6] [7] [8] One of the following regimens is recommended: 1. Ondansetron 16 mg to 24 mg orally (PO) and dexamethasone 12 mg PO, given 30 minutes before AD on days 1 through 4; aprepitant 125 mg PO, given 30 minutes before AD on day 1; and aprepitant 80 mg PO, given 30 minutes before AD on days 2 and 3. 2. Granisetron 2 mg PO and dexamethasone 12 mg PO, given 30 minutes before AD on days 1 through 4; aprepitant 125 mg PO, given 30 minutes before AD on day 1; and aprepitant 80 mg PO, given 30 minutes before AD on days 2 and 3. The antiemetic therapy should continue for at least 3 days after the last dose of chemotherapy. A meta-analysis of several trials of serotonin antagonists recommends against prolonged (greater than 24 hours) use of these agents, making a steroid, or steroid and dopamine antagonist combination, most appropriate for follow-up therapy. 10 One of the following regimens is recommended: 1. Dexamethasone 4 mg PO twice a day for 3 days ± metoclopramide 0.5 to 2 mg/kg PO every 4 to 6 hours ± diphenhydramine 25 to 50 mg PO every 6 hours if needed for restlessness, starting on day 5 of AD. 2. Dexamethasone 4 mg PO twice a day for 3 days ± prochlorperazine 10 mg PO every 4 to 6 hours ± diphenhydramine 25 to 50 mg PO every 6 hours if needed for restlessness, starting on day 5 of AD. 3. Dexamethasone 4 mg PO twice a day for 3 days ± promethazine 25 to 50 mg PO every 4 to 6 hours ± diphenhydramine 25 to 50 mg PO every 6 hours if needed, starting on day 5 of AD. B. Breakthrough Nausea and Vomiting [6] [7] [8] [9] : Patients should receive a prescription for an antiemetic to treat breakthrough nausea. One of the following regimens is recommended: 1. Metoclopramide 0.5 to 2 mg/kg PO every 4 to 6 hours if needed ± diphenhydramine 25 to 50 mg PO every 6 hours if needed for restlessness. Patients who do experience significant nausea or vomiting with one of these regimens should receive an agent from a different pharmacologic category. [11] [12] [13] [14] There is no evidence that substituting granisetron for ondansetron in subsequent treatment cycles, or increasing the dose, even to very high doses, is effective. This approach is not recommended.
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C. Hypersensitivity Precautions [16] [17] [18] : Doxorubicin can induce acute hypersensitivity reactions. However, such reactions are very rare and require no specific precautions. Doxorubicin may also cause a "flare reaction," manifested by erythema, pruritis, and urticaria surrounding the injection site, or extending along the vein being infused. Although sometimes confused with an extravasation or allergic reaction, generally it is self-limiting and resolves at the end of the infusion. Additional doses of the drug can be administered without concern. 16 D. Hematopoietic Growth Factors: Accepted practice guidelines and pharmaco economic analysis suggest that an antineoplastic regimen have a greater than 20% incidence of febrile neutropenia before prophylactic use of colony stimulating factors (CSFs) is warranted. For regimens with an incidence of febrile neutropenia between 10% and 20%, use of CSFs should be considered. For regimens with an incidence of febrile neutropenia less than 10%, routine prophylactic use of CSFs is not recommended. 19, 20 Since febrile neutropenia was not reported in the trials of AD reviewed, prophylactic use of CSFs is not recommended. 
